What is the appropriate evaluation for elevated liver enzymes when the abdominal ultrasound is normal?

Evaluation of Elevated Liver Enzymes with Normal Ultrasound

When liver enzymes are elevated but abdominal ultrasound is normal, proceed with systematic risk stratification based on the pattern of enzyme elevation (hepatocellular vs. cholestatic), followed by targeted serologic testing and non-invasive fibrosis assessment. 1, 2

Initial Pattern Recognition

Determine whether the injury pattern is hepatocellular (disproportionate ALT/AST elevation) or cholestatic (disproportionate alkaline phosphatase elevation), as this guides the diagnostic pathway. 2

• Hepatocellular pattern: ALT and AST elevated out of proportion to alkaline phosphatase
• Cholestatic pattern: Alkaline phosphatase elevated out of proportion to ALT/AST
• True normal ALT: 29-33 IU/L for males, 19-25 IU/L for females; levels above this warrant assessment 2

Hepatocellular Pattern Workup

First-Line Serologic Testing

Order the following tests systematically: 2, 3

• Viral hepatitis: Hepatitis A IgM, hepatitis B surface antigen and core antibody, hepatitis C antibody
• Metabolic conditions: Fasting glucose or HbA1c, lipid panel, BMI calculation
• Autoimmune: ANA, smooth muscle antibody, immunoglobulin levels
• Hereditary hemochromatosis: Transferrin saturation and ferritin
• Wilson's disease (if age <40): Ceruloplasmin, 24-hour urine copper
• Alpha-1 antitrypsin deficiency: Alpha-1 antitrypsin level and phenotype
• Medication review: All prescription, over-the-counter, herbal, and supplement use 2

Alcohol Assessment

• Use AUDIT-C as initial screening tool, followed by full 10-item AUDIT if positive 1
• High-risk thresholds: >50 units/week for men, >35 units/week for women 1
• AUDIT score >19 indicates alcohol dependency requiring referral to alcohol services 1
• Elevated GGT >100 U/L in any drinker warrants fibrosis assessment 1

Risk Stratification for NAFLD/MASLD

All patients with metabolic risk factors (type 2 diabetes, BMI >25, dyslipidemia, hypertension) require fibrosis risk stratification even with normal ultrasound. 1

Two-Step Fibrosis Assessment

Step 1 - First-line scoring (use either): 1

• FIB-4 score: Calculate using age, AST, ALT, and platelet count
• NAFLD Fibrosis Score (NFS): Calculate using age, BMI, glucose, AST, ALT, platelets, albumin

Step 2 - Second-line quantitative testing (if first-line indeterminate or positive): 1, 4

• Transient elastography (FibroScan):
  • <8-10 kPa rules out advanced fibrosis 4

  • 12-15 kPa suggests advanced fibrosis 4

  • Caution: AST >2× upper limit of normal causes false elevation; repeat after 1 week if AST elevated 4
• ELF test: Alternative quantitative serum marker 1, 4
• ARFI elastography: Alternative imaging-based assessment 1

Alcohol-Related Liver Disease Fibrosis Assessment

For harmful drinkers, perform clinical assessment plus FibroScan/ARFI elastography. 1

• Refer to secondary care if: FibroScan >16 kPa or features of cirrhosis/portal hypertension 1
• Active drinking with AST >2× ULN requires repeat measurement after ≥1 week of abstinence or reduced drinking 4

Cholestatic Pattern Workup

When alkaline phosphatase is disproportionately elevated: 2

• Confirm hepatic origin: GGT or 5'-nucleotidase elevation confirms liver source
• Primary biliary cholangitis: Anti-mitochondrial antibody, IgM level
• Primary sclerosing cholangitis: Consider MRCP if AMA negative and clinical suspicion exists 2

Mandatory Referral Criteria

Refer to hepatologist/gastroenterologist with liver expertise when: 1

• Negative extended liver workup but persistently elevated enzymes without NAFLD risk factors 1
• Advanced fibrosis detected (FibroScan >12-15 kPa, high FIB-4/NFS) 1, 4
• Evidence of cirrhosis or portal hypertension 1
• Autoimmune markers positive (noting that autoimmune hepatitis can present with negative antibodies and normal immunoglobulins) 1

Critical Pitfalls

• Normal ultrasound does not exclude advanced fibrosis or cirrhosis; non-invasive tests are essential 1
• Obesity and alcohol have synergistic effects: BMI >35 doubles liver disease risk at any alcohol intake 1
• 25% of patients with NAFLD risk factors may still have alcohol-related disease if they drink >14 units/week 1
• Autoimmune hepatitis can present with negative autoantibodies and normal immunoglobulins—entirely treatable conditions may be missed without specialist evaluation 1
• Elevated AST during active inflammation causes falsely elevated liver stiffness measurements 4